OpenEvidence Raises $250M at $12B Valuation in Series D Led by Thrive, DST

OpenEvidence has raised $250 million in a Series D round at a $12 billion valuation, co-led by Thrive Capital and DST Global on January 21, 2026. The funding follows strong user growth and revenue expansion, signaling investor confidence despite emerging competition from AI health tools by OpenAI and Anthropic. The round doubles its October 2025 valuation of $6 billion, when GV led a $200 million raise. To date, OpenEvidence has secured $700 million from investors including Sequoia, Nvidia, Kleiner Perkins, Blackstone, Bond, Craft Ventures, and Mayo Clinic. The platform supports verified U.S. healthcare professionals, delivering AI-powered medical insights akin to WebMD but tailored for clinicians. In December 2025, it facilitated 18 million clinical consultations—up from 3 million monthly searches a year earlier—and surpassed $100 million in revenue. Its primary competitors include Anthropic’s Claude for Healthcare and consumer-focused offerings like ChatGPT’s new health product.